Arix Bioscience plc Autolus presents additional AUTO3 data in DLBCL
May 29 2020 - 8:06AM
UK Regulatory
TIDMARIX
Arix Bioscience plc
Autolus presents additional AUTO3 data in DLBCL
LONDON, 29 May 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture
capital company focused on investing in and building breakthrough biotech
companies, notes that its portfolio company Autolus Therapeutics plc
("Autolus") (Nasdaq: AUTL), today announced new data highlighting progress on
AUTO3, the Autolus CAR T cell therapy being investigated in a Phase 1/2 study
in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during the Annual
Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program beginning
May 29.
The announcement can be accessed on Autolus' investor website at https://
www.autolus.com/investor-relations and full text of the announcement from
Autolus is contained below. Management will host a conference call and webcast
at 8:30 am EDT/1:30 pm BST on 1st June 2020 to discuss the ASCO data. To listen
to the webcast and view the accompanying slide deck, please go to: https://
www.autolus.com/investor-relations/news-and-events/events
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3714 1787
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in
and building breakthrough biotech companies around cutting edge advances in
life sciences. We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their ideas into
important new treatmentsfor patients. As a listed company, we are able to bring
this exciting growth phase of our industry to a broader range of investors.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the
ASCO20 Virtual Scientific Program
- Data continue to show encouraging clinical activity alongside tolerable
safety to deliver a potentially highly differentiated product profile -
Conference call and webcast to be held Monday, June 1, 2020 at 8:30 am EDT / 1:
30 pm BST
LONDON, May 29, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a
clinical-stage biopharmaceutical company developing next-generation programmed
T cell therapies, today announced new data highlighting progress on AUTO3, the
company's CAR T cell therapy being investigated in the ALEXANDER study, a Phase
1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during
the Annual Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific
Program beginning May 29.
"Data from the ALEXANDER trial of AUTO3, a CD19/CD22 dual-targeting CAR T
product candidate in DLBCL have shown a complete response rate of 63% at the
recommended Phase 2 dose range with an excellent safety profile," said Dr.
Aravind Ramakrishnan, Medical Director, Bone Marrow Transplant and Cellular
Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin
Medical Center. "We are encouraged by the current study results and have begun
enrollment in an outpatient cohort to assess how this approach may benefit a
greater population of DLBCL patients."
As of the data cut-off date of April 27, 2020, 23 patients in the ALEXANDER
Phase 1/2 clinical trial of AUTO3 were evaluable for safety and efficacy with a
minimum of 28-days follow-up. AUTO3 was well tolerated, with no patients
experiencing dose limiting toxicity, and there were no treatment-related
deaths. At a dose of ? 150 x 106 cells across the 2 dosing regimens for
pembrolizumab, a single dose of pembrolizumab on day minus 1 (D-1) or three
doses of pembrolizumab starting on day 14 (D14), no patient experienced Grade 3
or higher Cytokine Release Syndrome (CRS) and no patient experienced
neurotoxicity of any grade. At these doses, 11 out of 16 patients achieved a
complete or partial response (ORR=69%), and 9 out of 16 achieved a complete
response (CRR=56%) with all 9 complete responses ongoing at a median follow-up
of 3 months (range 1-12 months). Additionally, at the recommended Phase 2 dose
range of 150 - 450 x 106 cells with pembrolizumab D-1, 6 out of 8 patients
achieved a complete response or partial response (ORR=75%), and 5 out of 8
patients achieved a complete response (CRR=63%).
"We are very pleased with the progression of AUTO3 in DLBCL, combining a high
level of complete remissions with a safety profile supportive of outpatient
use. We have not seen early relapses from complete remissions and are in the
process of confirming the profile at the recommended Phase 2 regimen. Our 20
patient outpatient cohort has started, and the results are expected for the
second half of 2020 and will further inform the design of the Phase 2 study,"
said Dr. Christian Itin, chairman and chief executive officer of Autolus.
Investor call on Monday June 1, 2020
Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST
to discuss the ASCO data. To listen to the webcast and view the accompanying
slide presentation, please go to: https://www.autolus.com/investor-relations/
news-and-events/events.
The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada
callers or (409) 217-8320 for international callers. Please reference
conference ID 4880556. After the conference call, a replay will be available
for one week. To access the replay, please dial (855) 859-2056 for U.S. and
Canada callers or (404) 537-3406 for international callers. Please reference
conference ID 4880556.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of cancer. Using
a broad suite of proprietary and modular T cell programming technologies, the
company is engineering precisely targeted, controlled and highly active T cell
therapies that are designed to better recognize cancer cells, break down their
defense mechanisms and eliminate these cells. Autolus has a pipeline of product
candidates in development for the treatment of hematological malignancies and
solid tumors. For more information please visit www.autolus.com.
About AUTO3
AUTO3 is a programmed T cell therapy containing two independent chimeric
antigen receptors targeting CD19 and CD22 that have each been independently
optimized for single target activity. By simultaneously targeting two B cell
antigens, AUTO3 is designed to minimize relapse due to single antigen loss in
patients with B cell malignancies. AUTO3 is currently being tested in diffuse
large B cell lymphoma in the ALEXANDER clinical trial, with a 20-patient cohort
that was initiated in Q2 2020 to assess feasibility of treatment in an
outpatient setting.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are statements that are not historical facts,
and in some cases can be identified by terms such as "may," "will," "could,"
"expects," "plans," "anticipates," and "believes." These statements include,
but are not limited to, statements regarding Autolus' financial condition and
results of operations, including its expected cash runway; the development of
Autolus' product candidates, including statements regarding the timing of
initiation, completion and the outcome of pre-clinical studies or clinical
trials and related preparatory work, and the periods during which the results
of the studies and trials will become available; Autolus' plans to research,
develop, manufacture and commercialize its product candidates; the potential
for Autolus' product candidates to be alternatives in the therapeutic areas
investigated; and Autolus' manufacturing capabilities and strategy. Any
forward-looking statements are based on management's current views and
assumptions and involve risks and uncertainties that could cause actual
results, performance or events to differ materially from those expressed or
implied in such statements. For a discussion of other risks and uncertainties,
and other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the section
titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the
Securities and Exchange Commission on March 3, 2020 as well as discussions of
potential risks, uncertainties, and other important factors in Autolus' future
filings with the Securities and Exchange Commission from time to time. All
information in this press release is as of the date of the release, and the
company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise,
except as required by law.
Contact:
Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
END
(END) Dow Jones Newswires
May 29, 2020 08:06 ET (12:06 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2024 to Jun 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Jun 2023 to Jun 2024